CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Rapamycin

雷帕霉素 杂质对照品Rapamycin Impurities

27 个杂质条目27 impurity entries

本页汇总 雷帕霉素 的 27 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 27 impurity reference standards of Rapamycin. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 雷帕霉素(Rapamycin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsGenome instability footprint under rapamycin and hydroxyurea treatments
    PLoS genetics · 2023 · Li J et al.  ·  PMID 37931001  ·  DOI
  2. 分析方法Analytical MethodsLong-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas
    European journal of hospital pharmacy : science and practice · 2020 · Le Guyader G et al.  ·  PMID 32296505  ·  DOI
  3. 分析方法Analytical MethodsDetermination of rapamycin in whole blood by HPLC
    Therapeutic drug monitoring · 1997 · Svensson JO et al.  ·  PMID 9029760  ·  DOI

雷帕霉素 —— 原料药与杂质对照品Rapamycin — drug substance & impurities

共 27 个条目(含原料药本体)27 items incl. the drug substance
Rapamycin Impurity 1(27-O-Desmethyl Rapamycin) structure
1
雷帕霉素杂质1(27-O-去甲基雷帕霉素)Rapamycin Impurity 1(27-O-Desmethyl Rapamycin)
Rapamycin Impurity 1(27-O-Desmethyl Rapamycin)
CAS No.141392-23-6
Chemical FormulaC50H77NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 4 structure
4
雷帕霉素杂质4Rapamycin Impurity 4
Rapamycin Impurity 4
CAS No.150821-39-9
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 5 (42-O-Desmethyl Rapamycin) structure
5
雷帕霉素杂质5 (42-O-去甲基雷帕霉素)Rapamycin Impurity 5 (42-O-Desmethyl Rapamycin)
Rapamycin Impurity 5 (42-O-Desmethyl Rapamycin)
CAS No.142382-16-9
Chemical FormulaC50H77NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 6 (7-O-Desmethyl Rapamycin) structure
6
雷帕霉素杂质6 (7-O-去甲基雷帕霉素)Rapamycin Impurity 6 (7-O-Desmethyl Rapamycin)
Rapamycin Impurity 6 (7-O-Desmethyl Rapamycin)
CAS No.151519-50-5
Chemical FormulaC50H77NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 7(Demethoxy Rapamycin) structure
7
雷帕霉素杂质7(去甲基雷帕霉素)Rapamycin Impurity 7(Demethoxy Rapamycin)
Rapamycin Impurity 7(Demethoxy Rapamycin)
CAS No.83482-58-0
Chemical FormulaC50H77NO12
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 8 (Open-loop sirolimus) structure
8
雷帕霉素杂质8 (开环西罗莫司)Rapamycin Impurity 8 (Open-loop sirolimus)
Rapamycin Impurity 8 (Open-loop sirolimus)
CAS No.185107-79-3
Chemical FormulaC51H81NO14
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 11 (Prolylrapamycin) structure
11
雷帕霉素杂质11 (脯氨酰雷帕霉素)Rapamycin Impurity 11 (Prolylrapamycin)
Rapamycin Impurity 11 (Prolylrapamycin)
CAS No.156223-31-3
Chemical FormulaC50H77NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 13 structure
13
雷帕霉素杂质13Rapamycin Impurity 13
Rapamycin Impurity 13
CAS No.159351-88-9
Chemical FormulaC52H81NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 15 (7-O-Ethyl Rapamycin) structure
15
雷帕霉素杂质15 (7-O-乙基雷帕霉素)Rapamycin Impurity 15 (7-O-Ethyl Rapamycin)
Rapamycin Impurity 15 (7-O-Ethyl Rapamycin)
CAS No.157054-84-7
Chemical FormulaC52H81NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 16(28-epi-Rapamycin) structure
16
雷帕霉素杂质16(28-epi-雷帕霉素)Rapamycin Impurity 16(28-epi-Rapamycin)
Rapamycin Impurity 16(28-epi-Rapamycin)
CAS No.253431-35-5
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 17 (Rapamycin Dialdehyde) structure
17
雷帕霉素杂质17 (雷帕霉素二醛)Rapamycin Impurity 17 (Rapamycin Dialdehyde)
Rapamycin Impurity 17 (Rapamycin Dialdehyde)
CAS No.500733-49-3
Chemical FormulaC51H79NO15
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 20(Rapamycin-d3) structure
20
雷帕霉素杂质20(雷帕霉素-d3)Rapamycin Impurity 20(Rapamycin-d3)
Rapamycin Impurity 20(Rapamycin-d3)
CAS No.392711-19-2
Chemical FormulaC51H76D3NO13
Purity>95%询价On request
Rapamycin Impurity 23 structure
23
雷帕霉素杂质23Rapamycin Impurity 23
Rapamycin Impurity 23
CAS No.147438-27-5
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 26 structure
26
雷帕霉素杂质26Rapamycin Impurity 26
Rapamycin Impurity 26
CAS No.136293-03-3
Chemical FormulaC51H77NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 27 structure
27
雷帕霉素杂质27Rapamycin Impurity 27
Rapamycin Impurity 27
CAS No.1473389-19-3
Chemical FormulaC49H75NO12
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 28 structure
28
雷帕霉素杂质28Rapamycin Impurity 28
Rapamycin Impurity 28
CAS No.1062122-62-6
Chemical FormulaC53H84NO14P
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 29 structure
29
雷帕霉素杂质29Rapamycin Impurity 29
Rapamycin Impurity 29
CAS No.144293-63-0
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 30 structure
30
雷帕霉素杂质30Rapamycin Impurity 30
Rapamycin Impurity 30
CAS No.144370-88-7
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 31 structure
31
雷帕霉素杂质31Rapamycin Impurity 31
Rapamycin Impurity 31
CAS No.179076-04-1
Chemical FormulaC57H93NO13Si
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 32 structure
32
雷帕霉素杂质32Rapamycin Impurity 32
Rapamycin Impurity 32
CAS No.1237826-25-3
Chemical FormulaC52H79NO14
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 33 structure
33
雷帕霉素杂质33Rapamycin Impurity 33
Rapamycin Impurity 33
CAS No.143030-02-8
Chemical FormulaC57H93NO13Si
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 34 structure
34
雷帕霉素杂质34Rapamycin Impurity 34
Rapamycin Impurity 34
CAS No.1062645-51-5
Chemical FormulaC58H95N2O17P
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 35 structure
35
雷帕霉素杂质35Rapamycin Impurity 35
Rapamycin Impurity 35
CAS No.1392400-31-5
Chemical FormulaC61H101NO14Si
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 37 structure
37
雷帕霉素杂质37Rapamycin Impurity 37
Rapamycin Impurity 37
CAS No.151945-42-5
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 52 structure
52
雷帕霉素杂质52Rapamycin Impurity 52
Rapamycin Impurity 52
CAS No.157182-37-1
Chemical FormulaC51H79NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 58 structure
58
雷帕霉素杂质58Rapamycin Impurity 58
Rapamycin Impurity 58
CAS No.146352-12-7
Chemical FormulaC51H77NO13
Purity>95%询价On request
10mg25mg50mg100mg
Rapamycin Impurity 59 structure
59
雷帕霉素杂质59Rapamycin Impurity 59
Rapamycin Impurity 59
CAS No.204635-43-8
Chemical FormulaC51H77NO12
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

雷帕霉素 —— 研究文献与合成路线Rapamycin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 雷帕霉素 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Rapamycin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Forced degradation studies of rapamycin: identification of autoxidation products
    Oyler AR, Segmuller BE, Sun Y, et al. · Journal of pharmaceutical and biomedical analysis · 2012 · 被引 8cited 8
  2. The endosomal sorting complex required for transport pathway mediates chemokine receptor CXCR4-promoted lysosomal degradation of the mammalian target of rapamycin antagonist DEPTOR
    Verma R, Marchese A · The Journal of biological chemistry · 2015 · 被引 24cited 24
  3. Rapamycin enhances TNF-α-induced secretion of IL-6 and IL-8 through suppressing PDCD4 degradation in orbital fibroblasts
    Lee WM, Paik JS, Cho WK, et al. · Current eye research · 2013 · 被引 14cited 14
  4. Target of rapamycin signaling regulates starch degradation via α-glucan water dikinase in a unicellular red alga
    Komiya S, Pancha I, Shima H, et al. · Plant physiology · 2025 · 被引 6cited 6
  5. RNA polymerase II degradation in response to rapamycin is not mediated through ubiquitylation
    Jouvet N, Poschmann J, Douville J, et al. · Biochemical and biophysical research communications · 2011 · 被引 4cited 4
  6. Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients
    Zech SG, Carr M, Mohemmad QK, et al. · The Journal of antibiotics · 2011 · 被引 4cited 4

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES
    DAVE MAYANK GHANSHYAMBHAI, PANDEY BIPIN · 公开号 WO2011051960WO2011051960 · 2011
  2. SCALABLE PROCESS FOR THE PREPARATION OF A RAPAMYCIN 42-ESTER FROM A RAPAMYCIN 42-ESTER BORONATE
    ZHANG CHUNHAO, COUGHLIN CLIFFORD WILLIAM, PILCHER ANTHONY, MICHAUD ADAM P, et al. · 公开号 KR20080077619KR20080077619 · 2008
  3. PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES
    ACEMOGLU MURAT, PFEFFER SABINE · 公开号 KR20080090453KR20080090453 · 2008
  4. PROCESS FOR PREPARATION OF NOVEL 42-0-(HETEROALKOXYALKYL) RAPAMYCIN COMPOUNDS WITH ANTI-PROLIFERATIVE PROPERTIES"
    RANE DHANANJAY SHARAD, VYAS RAJNIKANT GANDALAL, MINOCHA PRAMOD KUMAR · 公开号 WO2012017449WO2012017449 · 2012
  5. Methods of Manufacturing Crystalline Forms of Rapamycin Analogs
    VISWANATH SHEKHAR, BARTELT LARRY, LEANNA ROBERT, RASMUSSEN MICHAEL, et al. · 公开号 US2012028908US2012028908 · 2012

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

雷帕霉素 杂质谱研究要点Rapamycin — impurity profiling notes

下面这些是拿到 雷帕霉素 的 27 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 27 impurity entries for Rapamycin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances